People | June 04, 2026
Alembic appoints Ramesh Juneja as Executive Vice President – Human Health for India business
Juneja brings more than three decades of experience in pharmaceutical sales and marketing
Juneja brings more than three decades of experience in pharmaceutical sales and marketing
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
In this role, Romanelli will have P&L responsibility for Merck’s US $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S
In the interim, Deepak Khanna will lead Human Health International.
With over three decades of extensive industry experience, Ramesh Juneja brings a strong track record of building and scaling large businesses
Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
Health innovations are viewed more positively than food and agricultural technologies
Collaboration integrates SmartChip PCR technology with cloud-based analytics to enable faster, standardised monitoring of antimicrobial resistance
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Subscribe To Our Newsletter & Stay Updated
